Cargando…

Pharmacotherapy for multidrug resistant tuberculosis

The current global concern in the treatment of tuberculosis (TB) is the emergence of resistance to the two most potent drugs namely, isoniazid and rifampicin. Emergence of multidrug resistance tuberculosis (MDR-TB) is now a health problem faced by most of the developing countries as well as develope...

Descripción completa

Detalles Bibliográficos
Autores principales: Chhabra, Naveen, Aseri, M. L., Dixit, Ramakant, Gaur, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356975/
https://www.ncbi.nlm.nih.gov/pubmed/22629081
http://dx.doi.org/10.4103/0976-500X.95502
_version_ 1782233618407489536
author Chhabra, Naveen
Aseri, M. L.
Dixit, Ramakant
Gaur, S.
author_facet Chhabra, Naveen
Aseri, M. L.
Dixit, Ramakant
Gaur, S.
author_sort Chhabra, Naveen
collection PubMed
description The current global concern in the treatment of tuberculosis (TB) is the emergence of resistance to the two most potent drugs namely, isoniazid and rifampicin. Emergence of multidrug resistance tuberculosis (MDR-TB) is now a health problem faced by most of the developing countries as well as developed countries across the globe. MDR-TB is a man-made disease that is caused by improper treatment, inadequate drug supplies, and poor patient supervision. HIV infection and AIDS have been implicated as important cause for this. The review of a published literature suggests that the most powerful predictor of treatment of MDR-TB is a history of treatment of TB. Although the treatment is efficacious, there are also a number of adverse effects caused by drugs used in the treatment of MDR-TB.
format Online
Article
Text
id pubmed-3356975
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-33569752012-05-24 Pharmacotherapy for multidrug resistant tuberculosis Chhabra, Naveen Aseri, M. L. Dixit, Ramakant Gaur, S. J Pharmacol Pharmacother Educational Forum The current global concern in the treatment of tuberculosis (TB) is the emergence of resistance to the two most potent drugs namely, isoniazid and rifampicin. Emergence of multidrug resistance tuberculosis (MDR-TB) is now a health problem faced by most of the developing countries as well as developed countries across the globe. MDR-TB is a man-made disease that is caused by improper treatment, inadequate drug supplies, and poor patient supervision. HIV infection and AIDS have been implicated as important cause for this. The review of a published literature suggests that the most powerful predictor of treatment of MDR-TB is a history of treatment of TB. Although the treatment is efficacious, there are also a number of adverse effects caused by drugs used in the treatment of MDR-TB. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3356975/ /pubmed/22629081 http://dx.doi.org/10.4103/0976-500X.95502 Text en Copyright: © Journal of Pharmacology and Pharmacotherapeutics http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Educational Forum
Chhabra, Naveen
Aseri, M. L.
Dixit, Ramakant
Gaur, S.
Pharmacotherapy for multidrug resistant tuberculosis
title Pharmacotherapy for multidrug resistant tuberculosis
title_full Pharmacotherapy for multidrug resistant tuberculosis
title_fullStr Pharmacotherapy for multidrug resistant tuberculosis
title_full_unstemmed Pharmacotherapy for multidrug resistant tuberculosis
title_short Pharmacotherapy for multidrug resistant tuberculosis
title_sort pharmacotherapy for multidrug resistant tuberculosis
topic Educational Forum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356975/
https://www.ncbi.nlm.nih.gov/pubmed/22629081
http://dx.doi.org/10.4103/0976-500X.95502
work_keys_str_mv AT chhabranaveen pharmacotherapyformultidrugresistanttuberculosis
AT aseriml pharmacotherapyformultidrugresistanttuberculosis
AT dixitramakant pharmacotherapyformultidrugresistanttuberculosis
AT gaurs pharmacotherapyformultidrugresistanttuberculosis